Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes

ABSTRACT Pure, plant-based CBD is a pharmaceutical grade extract that exhibits clinically significant antiseizure properties, with a hypothesized multimodal mechanism of action. In the GWPCARE trial series, CBD displayed superior efficacy in reducing key seizure frequencies (convulsive seizures in DS; drop seizures in LGS) by 17% to 23% compared with placebo as adjunctive therapy to …

Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes Read More »